MTCO2P17

Across TCGA pan-cancer cohorts, MTCO2P17 RNA is linked to patient survival in 17 of 34 cancer types, making it the most broadly survival-associated MTCO2P17 data layer.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher MTCO2P17 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated MTCO2P17 expression acts as an unfavorable survival marker, although some lineages such as UCS and GBM show a favorable association.

KIRC, MESO, and LIHC are the cancer types where MTCO2P17 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	DFS	Tertile	III,IV	0.274	0.664	.001	60	view →
MESO	OS	Tertile	III,IV	0.393	0.607	.019	54	view →
LIHC	DFS	Tertile	II,III,IV	0.040	0.427	<.001	45	view →
BRCA	DFS	Tertile	All	0.570	1.000	.033	36	view →
UCS	OS	Tertile	IV	0.844	0.250	.016	30	view →
GBM	OS	Tertile	All	0.615	0.383	.016	21	view →
THCA	OS	Tertile	III,IV	0.741	0.977	.023	18	view →
STAD	OS	Tertile	III,IV	0.192	0.550	.011	18	view →
COAD	DFS	Tertile	II,III,IV	0.422	0.663	.026	18	view →
UVM	DFS	Tertile	III,IV	0.079	0.674	.020	18	view →
SKCM	DFS	Tertile	II,III,IV	0.104	0.235	.035	12	view →
PCPG	OS	Tertile	All	0.539	0.954	.021	9	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 17 lineages.

MTCO2P17–KIRC (DFS)

Open the KIRC breakdown →